Total Payments
$4.1M
2024 Payments
$407,601
Companies
56
Transactions
5,184
Medicare Patients
2,940
Medicare Billing
$351,904
Payment Breakdown by Category
Other$3.1M (74.8%)
Travel$612,091 (14.8%)
Consulting$311,104 (7.5%)
Food & Beverage$85,135 (2.1%)
Research$29,235 (0.7%)
Education$2,599 (0.1%)
Gifts$178.20 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.0M | 1,735 | 73.6% |
| Travel and Lodging | $612,091 | 1,329 | 14.8% |
| Consulting Fee | $311,104 | 142 | 7.5% |
| Food and Beverage | $85,135 | 1,758 | 2.1% |
| Unspecified | $29,235 | 65 | 0.7% |
| Honoraria | $22,950 | 14 | 0.6% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $13,750 | 12 | 0.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $13,038 | 11 | 0.3% |
| Education | $2,599 | 115 | 0.1% |
| Gift | $178.20 | 3 | 0.0% |
Payments by Type
General
$4.1M
5,119 transactions
Research
$29,235
65 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $858,892 | 1,175 | $0 (2024) |
| Novo Nordisk Inc | $642,479 | 739 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $633,548 | 667 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $380,128 | 375 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $300,390 | 333 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $253,986 | 319 | $0 (2024) |
| Amgen Inc. | $212,424 | 293 | $0 (2024) |
| Amarin Pharma Inc. | $201,328 | 214 | $0 (2022) |
| Bayer Healthcare Pharmaceuticals Inc. | $166,979 | 130 | $0 (2024) |
| Merck Sharp & Dohme LLC | $99,077 | 109 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $407,601 | 456 | SANOFI-AVENTIS U.S. LLC ($96,387) |
| 2023 | $287,864 | 440 | Lilly USA, LLC ($105,386) |
| 2022 | $335,672 | 412 | Novo Nordisk Inc ($87,788) |
| 2021 | $405,376 | 501 | Lilly USA, LLC ($124,341) |
| 2020 | $306,513 | 426 | Lilly USA, LLC ($131,004) |
| 2019 | $662,398 | 883 | Lilly USA, LLC ($146,891) |
| 2018 | $788,303 | 945 | SANOFI-AVENTIS U.S. LLC ($180,015) |
| 2017 | $936,125 | 1,121 | SANOFI-AVENTIS U.S. LLC ($259,838) |
All Payment Transactions
5,184 individual payment records from CMS Open Payments — Page 1 of 208
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | PFIZER INC. | SOMAVERT (Drug), GENOTROPIN | Food and Beverage | In-kind items and services | $15.45 | General |
| Category: ENDOCRINE DISEASE;METABOLIC DISEASE | ||||||
| 12/11/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $27.52 | General |
| Category: Diabetes | ||||||
| 12/11/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $22.86 | General |
| Category: Diabetes Care | ||||||
| 12/10/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Diabetes | ||||||
| 12/06/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Honoraria | Cash or cash equivalent | $2,450.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/05/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,773.00 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 12/05/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Travel and Lodging | In-kind items and services | $258.42 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 12/03/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $26.55 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 11/26/2024 | Esperion Therapeutics, Inc. | NEXLIZET (Drug), NEXLETOL | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,460.00 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 11/26/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Diabetes Care | ||||||
| 11/25/2024 | PFIZER INC. | SOMAVERT (Drug), GENOTROPIN | Food and Beverage | In-kind items and services | $14.16 | General |
| Category: ENDOCRINE DISEASE;METABOLIC DISEASE | ||||||
| 11/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,098.00 | General |
| Category: Cardio-renal | ||||||
| 11/20/2024 | Esperion Therapeutics, Inc. | NEXLIZET (Drug), NEXLETOL | Food and Beverage | In-kind items and services | $113.28 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 11/19/2024 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $16.21 | General |
| Category: Bone Health | ||||||
| 11/18/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| Category: Diabetes | ||||||
| 11/18/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,325.00 | General |
| Category: Diabetes | ||||||
| 11/15/2024 | Novo Nordisk Inc | Wegovy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $938.00 | General |
| Category: Obesity | ||||||
| 11/13/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $1,556.83 | General |
| 11/13/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | Cash or cash equivalent | $124.23 | General |
| Category: Diabetes | ||||||
| 11/12/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $15.43 | General |
| 11/11/2024 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $3.20 | General |
| Category: Bone Health | ||||||
| 11/08/2024 | Novo Nordisk Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| 11/07/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $8,063.00 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 11/07/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Travel and Lodging | In-kind items and services | $899.82 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 11/07/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Travel and Lodging | In-kind items and services | $608.61 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| NN9535-4321 | Novo Nordisk AS | $5,100 | 5 |
| AchieveControl AMCPNx pst; A randomized prospective pragmatic real-world (RW) clinical trial of insulin glargine 300 U/mL (Gla-300) vs other basal insulins (BIs) in insulin-naive patients with type 2 | SANOFI-AVENTIS U.S. LLC | $3,349 | 4 |
| CATALYST | Corcept Therapeutics | $2,340 | 8 |
| A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | Eli Lilly and Company | $2,198 | 3 |
| A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism | ABBVIE INC. | $1,855 | 7 |
| A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL COMPARING EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS SEMAGLUTIDE ONCE WEEKLY AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $1,781 | 2 |
| NN9535-4321 & EX9924-4473 | Novo Nordisk AS | $1,619 | 6 |
| A randomized, open-label, parallel group real world pragmatic trial to assess the clinical and health outcomes of Toujeo compared to commercially available basal insulins for initiation of therapy in | SANOFI-AVENTIS U.S. LLC | $1,598 | 1 |
| NN SELECT Results Meeting Philadelphia | Novo Nordisk AS | $1,332 | 8 |
| A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM) | SANOFI-AVENTIS U.S. LLC | $1,300 | 3 |
| A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) | Eli Lilly and Company | $1,214 | 1 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease | Gilead Sciences, Inc. | $970.27 | 10 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | Eli Lilly and Company | $623.00 | 1 |
| ACHIEVE CONTROL | SANOFI-AVENTIS U.S. LLC | $392.04 | 1 |
| A Real World Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM) | SANOFI-AVENTIS U.S. LLC | $308.55 | 1 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi | SANOFI US SERVICES INC. | $306.68 | 2 |
| NN9535-4352 | Novo Nordisk Inc | $24.99 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 407 | 530 | $127,173 | $27,696 |
| 2022 | 7 | 629 | 795 | $212,924 | $50,001 |
| 2021 | 7 | 736 | 1,046 | $243,068 | $69,272 |
| 2020 | 14 | 1,168 | 8,623 | $799,948 | $204,935 |
Total Patients
2,940
Total Services
10,994
Medicare Billing
$351,904
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 290 | 404 | $114,016 | $25,749 | 22.6% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 27 | 36 | $4,680 | $898.69 | 19.2% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 77 | 77 | $5,929 | $701.47 | 11.8% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 13 | 13 | $2,548 | $347.49 | 13.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 394 | 550 | $163,636 | $37,212 | 22.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 72 | 72 | $27,902 | $9,233 | 33.1% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 30 | 38 | $4,940 | $1,009 | 20.4% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2022 | 89 | 89 | $6,853 | $842.36 | 12.3% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 15 | 17 | $4,607 | $732.23 | 15.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 18 | 18 | $3,600 | $675.21 | 18.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 11 | 11 | $1,386 | $297.33 | 21.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 449 | 733 | $176,309 | $48,325 | 27.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 91 | 91 | $31,031 | $11,896 | 38.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 27 | 46 | $14,344 | $4,694 | 32.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 12 | 12 | $5,820 | $1,441 | 24.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 24 | 27 | $4,077 | $1,283 | 31.5% |
| 77080 | Bone density measurement of the core or central skeleton (e.g., hips, pelvis, spine) | Office | 2021 | 120 | 120 | $9,277 | $1,157 | 12.5% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 13 | 17 | $2,210 | $477.02 | 21.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2020 | 78 | 7,020 | $342,351 | $108,199 | 31.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 445 | 773 | $261,709 | $53,128 | 20.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 104 | 104 | $35,464 | $11,846 | 33.4% |
| 93880 | Ultrasound scanning of blood flow (outside the brain) on both sides of head and neck | Office | 2020 | 45 | 91 | $35,524 | $6,160 | 17.3% |
| 77080 | Bone density measurement using dedicated x-ray machine | Office | 2020 | 130 | 130 | $35,882 | $4,572 | 12.7% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 37 | 37 | $17,520 | $4,023 | 23.0% |
| 76536 | Ultrasound of head and neck | Office | 2020 | 37 | 79 | $15,544 | $3,243 | 20.9% |
About Dr. Robert Busch, M.D
Dr. Robert Busch, M.D is a Endocrinology, Diabetes & Metabolism healthcare provider based in Albany, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/01/2005. The National Provider Identifier (NPI) number assigned to this provider is 1457358715.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Busch, M.D has received a total of $4.1M in payments from pharmaceutical and medical device companies, with $407,601 received in 2024. These payments were reported across 5,184 transactions from 56 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($3.0M).
As a Medicare-enrolled provider, Busch has provided services to 2,940 Medicare beneficiaries, totaling 10,994 services with total Medicare billing of $351,904. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Albany, NY
- Active Since 07/01/2005
- Last Updated 11/13/2009
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1457358715
Products in Payments
- JARDIANCE (Drug) $467,105
- TRULICITY (Drug) $420,148
- INVOKANA (Drug) $363,730
- SOLIQUA (Drug) $251,797
- FARXIGA (Drug) $228,930
- Repatha (Biological) $211,814
- Vascepa (Drug) $201,328
- Kerendia (Drug) $166,979
- TOUJEO (Drug) $157,065
- Ozempic (Drug) $142,333
- MOUNJARO (Drug) $126,098
- TZIELD (Biological) $111,497
- STEGLATRO (Drug) $92,658
- Saxenda (Drug) $91,664
- NEXLIZET (Drug) $88,874
- Wegovy (Drug) $77,549
- Victoza (Drug) $74,172
- RYBELSUS (Drug) $64,202
- BYDUREON (Drug) $61,838
- Tresiba (Drug) $51,318
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Albany
Dr. Gregg Gerety, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $665,599
Endocrinology, Diabetes & Metabolism $665,599
Dr. Jay Watsky, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $83,103
Endocrinology, Diabetes & Metabolism $83,103
Dr. Mark Fruiterman, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $37,168
Endocrinology, Diabetes & Metabolism $37,168
Dr. Michael Walker, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $17,934
Endocrinology, Diabetes & Metabolism $17,934
Dr. Gary Bakst, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $17,831
Endocrinology, Diabetes & Metabolism $17,831
Dr. Samer Eldeiry, M.d., Ph.d, M.D., PH.D
Endocrinology, Diabetes & Metabolism — Payments: $9,611
Endocrinology, Diabetes & Metabolism $9,611